Validation of a Transcriptome-Based Assay for Classifying Cancers of Unknown Primary Origin.

Jackson MichudaAlessandra BreschiJoshuah KapilivskyKabir ManghnaniCalvin McCarterAdam J HockenberryBrittany MineoCatherine IgartuaJoel T DudleyMartin C StumpeNike BeaubierMaryam ShiraziRyan JonesElizabeth MorencyKim BlackwellJustin GuinneyKyle A BeauchampTimothy Taxter

Published in: Molecular diagnosis & therapy (2023)

Combining diagnostic prediction tests (e.g., Tempus TO) with sequencing-based variant reporting (e.g., Tempus xT) may expand therapeutic options for patients with cancers of unknown primary or uncertain histology.

Keyphrases

single cell
high throughput
gene expression
genome wide
adverse drug
young adults
childhood cancer